Literature DB >> 19745842

Vesicular stomatitis virus inhibits mitotic progression and triggers cell death.

Papia Chakraborty1, Joachim Seemann, Ram K Mishra, Jen-Hsuan Wei, Lauren Weil, Daniel R Nussenzveig, Joshua Heiber, Glen N Barber, Mary Dasso, Beatriz M A Fontoura.   

Abstract

Vesicular stomatitis virus (VSV) infects and kills a wide range of cell types; however, the mechanisms involved in VSV-mediated cell death are not fully understood. Here we show that VSV infection interferes with mitotic progression, resulting in cell death. This effect requires the interaction of VSV matrix (M) protein with the Rae1-Nup98 complex in mitosis, which is associated with a subset of ribonucleoproteins (RNPs). VSV displaced Rae1 from spindle poles, caused spindle abnormalities and triggered substantial cell death during metaphase. These effects were attenuated in cells infected with VSV expressing a mutant M protein that does not bind efficiently to the Rae1-Nup98-RNP complex. In cells that progressed to late mitosis, M protein prevented proper nuclear formation and chromatin decondensation. VSV is an oncolytic (anti-tumour) agent as it preferentially replicates and kills tumour cells. As tumour cells have a high mitotic index, VSV-mediated mitotic cell death probably contributes to its oncolytic activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19745842      PMCID: PMC2759734          DOI: 10.1038/embor.2009.179

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  18 in total

1.  Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98.

Authors:  J P Rodrigues; D Sitterlin; A Bachi; X Wu; M Wilm; M Carmo-Fonseca; E Izaurralde
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

2.  A Rae1-containing ribonucleoprotein complex is required for mitotic spindle assembly.

Authors:  Michael D Blower; Maxence Nachury; Rebecca Heald; Karsten Weis
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

3.  Role of nucleoporin induction in releasing an mRNA nuclear export block.

Authors:  Jost Enninga; David E Levy; Günter Blobel; Beatriz M A Fontoura
Journal:  Science       Date:  2002-01-24       Impact factor: 47.728

4.  Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus.

Authors:  L S Her; E Lund; J E Dahlberg
Journal:  Science       Date:  1997-06-20       Impact factor: 47.728

Review 5.  Vesicular stomatitis virus as an oncolytic vector.

Authors:  Glen N Barber
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

6.  VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway.

Authors:  Paula A Faria; Papia Chakraborty; Agata Levay; Glen N Barber; Heather J Ezelle; Jost Enninga; Carlos Arana; Jan van Deursen; Beatriz M A Fontoura
Journal:  Mol Cell       Date:  2005-01-07       Impact factor: 17.970

7.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Defective translational control facilitates vesicular stomatitis virus oncolysis.

Authors:  Siddharth Balachandran; Glen N Barber
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

9.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Reconstituted nuclei depleted of a vertebrate GLFG nuclear pore protein, p97, import but are defective in nuclear growth and replication.

Authors:  M A Powers; C Macaulay; F R Masiarz; D J Forbes
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  15 in total

Review 1.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

2.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

3.  Inclusion bodies are a site of ebolavirus replication.

Authors:  Thomas Hoenen; Reed S Shabman; Allison Groseth; Astrid Herwig; Michaela Weber; Gordian Schudt; Olga Dolnik; Christopher F Basler; Stephan Becker; Heinz Feldmann
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

Review 4.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

5.  Vesiculoviral matrix (M) protein occupies nucleic acid binding site at nucleoporin pair (Rae1 • Nup98).

Authors:  Beili Quan; Hyuk-Soo Seo; Günter Blobel; Yi Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

Review 6.  The Quest for the Blueprint of the Nuclear Pore Complex.

Authors:  Joseph S Glavy
Journal:  Protein J       Date:  2019-08       Impact factor: 2.371

7.  A Herpesvirus Protein Selectively Inhibits Cellular mRNA Nuclear Export.

Authors:  Danyang Gong; Yong Hoon Kim; Yuchen Xiao; Yushen Du; Yafang Xie; Kevin K Lee; Jun Feng; Nisar Farhat; Dawei Zhao; Sara Shu; Xinghong Dai; Sumit K Chanda; Tariq M Rana; Nevan J Krogan; Ren Sun; Ting-Ting Wu
Journal:  Cell Host Microbe       Date:  2016-11-09       Impact factor: 21.023

8.  Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.

Authors:  Sabrina Marozin; Enrico N De Toni; Antonia Rizzani; Jennifer Altomonte; Alexandra Junger; Günter Schneider; Wolfgang E Thasler; Nobuyuki Kato; Roland M Schmid; Oliver Ebert
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

9.  Characterization of the role of the tumor marker Nup88 in mitosis.

Authors:  Chieko Hashizume; Hiroshi Nakano; Kimihisa Yoshida; Richard W Wong
Journal:  Mol Cancer       Date:  2010-05-24       Impact factor: 27.401

Review 10.  Nuclear trafficking in health and disease.

Authors:  Amir Mor; Michael A White; Beatriz M A Fontoura
Journal:  Curr Opin Cell Biol       Date:  2014-02-11       Impact factor: 8.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.